摘要
目的:研究骨肉瘤中HER2基因的表达与临床预后的关系。方法:对82例骨肉瘤患者的临床病理资料进行回顾性研究,应用HER2单克隆抗体对组织切片进行免疫组织化学染色,并将上述资料与患者的预后进行分析。结果:骨肉瘤患者HER2表达与患者预后相关(P<0.05),HER2高表达的骨肉瘤患者预后较差。结论:HER2检测是骨肉瘤预后判断的一项有价值的指标;同时,HER2为骨肉瘤的治疗提供一种可能的生物靶点。
Objective：To evaluate the relationship between prognostic significance and the expression of HER2 in osteosarcoma. Methods： The clinicopathologic information of eighty - two patients with osteosarcoma was studied retrospectively. By using anti - HER2 monoclonal antibody, the expression of HER2 was assessed by standard immunohistochemical staining. The data together with the prognosis of patients were analyzed statistically. Results： The expression of HER2 was correlated with the patients＇prognostic （P 〈 0.05 ）. Conclusion： HER2 expression is one of the important prognostic factors in osteosarcoma. The correlation also suggests HER2 could be considered as a possible target for the gene therapy of osteosarcoma.
出处
《现代肿瘤医学》
CAS
2006年第6期742-744,共3页
Journal of Modern Oncology
基金
国家自然科学基金资助项目(No.30471988)
